冠状病毒 2019 治疗效果比较的生存分析研究。
Survival Analysis of Treatment Efficacy in Comparative Coronavirus Disease 2019 Studies.
机构信息
Google, Mountain View, California, USA.
Department of Biomedical Data Science, Stanford University, Stanford, California, USA.
出版信息
Clin Infect Dis. 2021 Jun 1;72(11):e887-e889. doi: 10.1093/cid/ciaa1563.
Abstract
For survival analysis in comparative coronavirus disease 2019 trials, the routinely used hazard ratio may not provide a meaningful summary of the treatment effect. The mean survival time difference/ratio is an intuitive, assumption-free alternative. However, for short-term studies, landmark mortality rate differences/ratios are more clinically relevant and should be formally analyzed and reported.
摘要
对于比较 2019 年冠状病毒病的临床试验中的生存分析，常规使用的风险比可能无法对治疗效果进行有意义的总结。平均生存时间差异/比是一种直观、无假设的替代方法。但是，对于短期研究，里程碑死亡率差异/比更具有临床相关性，应该进行正式分析和报告。
相似文献
1
Survival Analysis of Treatment Efficacy in Comparative Coronavirus Disease 2019 Studies.冠状病毒 2019 治疗效果比较的生存分析研究。
Clin Infect Dis. 2021 Jun 1;72(11):e887-e889. doi: 10.1093/cid/ciaa1563.
2
Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.COVID-19 住院成人患者使用伊马替尼的安全性和疗效：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Oct 28;21(1):897. doi: 10.1186/s13063-020-04819-9.
3
Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19.氯喹或羟氯喹预防和治疗 COVID-19。
Cochrane Database Syst Rev. 2021 Feb 12;2(2):CD013587. doi: 10.1002/14651858.CD013587.pub2.
4
A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.一项评估 SARS-CoV-2 疫苗（灭活，Vero 细胞）有效性和安全性的随机、双盲、安慰剂对照 III 期临床试验：一项随机对照试验研究方案的结构化总结。
Trials. 2021 Apr 13;22(1):276. doi: 10.1186/s13063-021-05180-1.
5
Association of Red Blood Cell Distribution Width With Mortality Risk in Hospitalized Adults With SARS-CoV-2 Infection.红细胞分布宽度与住院成人 SARS-CoV-2 感染患者死亡风险的关联。
JAMA Netw Open. 2020 Sep 1;3(9):e2022058. doi: 10.1001/jamanetworkopen.2020.22058.
6
Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio.使用受限平均生存时间替代风险比来解释癌症临床试验结果的可解释性。
JAMA Oncol. 2017 Dec 1;3(12):1692-1696. doi: 10.1001/jamaoncol.2017.2797.
7
Evaluating whether the proportional odds models to analyse ordinal outcomes in COVID-19 clinical trials is providing clinically interpretable treatment effects: A systematic review.评估 COVID-19 临床试验中分析有序结局的比例优势模型是否提供了具有临床可解释性的治疗效果：一项系统评价。
Clin Trials. 2024 Jun;21(3):363-370. doi: 10.1177/17407745231211272. Epub 2023 Nov 20.
8
Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks.用恢复期血浆治疗 COVID-19：从过去的冠状病毒爆发中吸取的教训。
Clin Microbiol Infect. 2020 Oct;26(10):1436-1446. doi: 10.1016/j.cmi.2020.08.005. Epub 2020 Aug 11.
9
Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.评估 BIO101 预防 COVID-19 肺炎患者呼吸恶化的疗效和安全性（COVA 研究）：一项随机对照试验研究方案的结构化总结。
Trials. 2021 Jan 11;22(1):42. doi: 10.1186/s13063-020-04998-5.
10
Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.评估人抗 SARS-CoV-2 恢复期血浆在 COVID-19 重症成人中的疗效和安全性：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jun 8;21(1):499. doi: 10.1186/s13063-020-04422-y.
引用本文的文献
1
Definitions and elements of endpoints in phase III randomized trials for the treatment of COVID-19: a cross-sectional analysis of trials registered in ClinicalTrials.gov.COVID-19 治疗的 III 期随机临床试验终点的定义和要素：对 ClinicalTrials.gov 注册试验的横断面分析。
Trials. 2021 Nov 8;22(1):788. doi: 10.1186/s13063-021-05763-y.
2
Efficacy of COVID-19 Treatments: A Bayesian Network Meta-Analysis of Randomized Controlled Trials.COVID-19 治疗效果的贝叶斯网状 Meta 分析：随机对照试验研究。
Front Public Health. 2021 Sep 28;9:729559. doi: 10.3389/fpubh.2021.729559. eCollection 2021.
本文引用的文献
1
Evaluating the Efficacy of Therapies in Patients With Coronavirus Disease 2019.评估 2019 年冠状病毒病患者治疗方法的疗效。
Clin Infect Dis. 2021 Mar 15;72(6):1093-1100. doi: 10.1093/cid/ciaa1231.
2
Remdesivir for the Treatment of Covid-19 - Preliminary Report. Reply.瑞德西韦治疗新冠病毒病-初步报告。回复。
N Engl J Med. 2020 Sep 3;383(10):994. doi: 10.1056/NEJMc2022236. Epub 2020 Jul 10.
3
Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio.使用受限平均生存时间替代风险比来解释癌症临床试验结果的可解释性。
JAMA Oncol. 2017 Dec 1;3(12):1692-1696. doi: 10.1001/jamaoncol.2017.2797.
4
Restricted Mean Survival Time as a Measure to Interpret Clinical Trial Results.受限平均生存时间作为解释临床试验结果的一种度量方法。
JAMA Cardiol. 2017 Nov 1;2(11):1179-1180. doi: 10.1001/jamacardio.2017.2922.
5
Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis.超越风险比：在生存分析中量化组间差异。
J Clin Oncol. 2014 Aug 1;32(22):2380-5. doi: 10.1200/JCO.2014.55.2208. Epub 2014 Jun 30.
6
Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves.增强型生存数据分析：从已发表的 Kaplan-Meier 生存曲线中重建数据。
BMC Med Res Methodol. 2012 Feb 1;12:9. doi: 10.1186/1471-2288-12-9.
Zotero 插件